(Q28371460)

English

ALK EML4::ALK e6-e20

genetic variant

EML4-ALK E6;A20
EML4-ALK e6-e20
EML4::ALK e6-e20

In more languages

Statements

transcript fusion

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/503

human chromosome 2

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/503

42396490

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/503

29415640

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/503

42491871

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/503

29446394

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/503

biological variant of

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/503

positive therapeutic predictor for

medical condition treated

non-small-cell lung carcinoma

determination method

CIViC evidence level D

CIViC 3-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1340

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer

medical condition treated

non-small-cell lung carcinoma

statement disputed by

Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.

determination method

CIViC evidence level D

CIViC 2-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1197

Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.

medical condition treated

non-small-cell lung carcinoma

statement disputed by

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer

determination method

CIViC evidence level D

CIViC 2-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1195

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer

medical condition treated

non-small-cell lung carcinoma

determination method

CIViC evidence level D

CIViC 2-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1194

Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors

2,4-diaminopyrimidine

medical condition treated

non-small-cell lung carcinoma

determination method

CIViC evidence level D

CIViC 4-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1192

Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.

medical condition treated

non-small-cell lung carcinoma

determination method

CIViC evidence level C

CIViC 4-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1193

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

Identifiers

CIViC variant ID

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/503

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28371460&oldid=2014799522"